Azacitidine - Pfizer

Drug Profile

Azacitidine - Pfizer

Alternative Names: 5-azacytidine; Aza-C; Azacytidine; CC-486; Ladakamycin; NS-17; NSC-102816; U-18496; Vidaza

Latest Information Update: 12 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmacia Corporation
  • Developer Australasian Leukaemia & Lymphoma Group; Celgene Corporation; H. Lee Moffitt Cancer Center and Research Institute; Karolinska University Hospital; Nippon Shinyaku; Pfizer; University Hospital Regensburg; University of Colorado at Denver; University of Kansas Medical Center; University of Texas M. D. Anderson Cancer Center; University of Utah; Washington University School of Medicine; Weill Cornell Medical College
  • Class Antineoplastics; Aza compounds; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase II Breast cancer; Leukaemia; Nasopharyngeal cancer; Non-small cell lung cancer
  • Phase I/II Colorectal cancer; Diffuse large B cell lymphoma; Renal cancer; Solid tumours
  • Phase I Lymphoma
  • No development reported Multiple myeloma

Most Recent Events

  • 09 Dec 2017 Efficacy, safety and pharmacodynamics data from a phase I trial in Lymphoma presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
  • 09 Dec 2017 Safety and efficacy data from a phase I/II trial in Acute myeloid leukaemia and Myelodysplastic syndrome were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
  • 05 Dec 2017 Adverse events and efficacy data from a phase II trial in metastatic Breast cancer presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top